Simultaneous monitoring of inhibition of serotonin uptake by platelates and plasma drug concentrations following administration of duloxetine, a new antidepressant candidate, to healthy volunteers

Current Therapeutic Research - Clinical and Experimental

Volumn 58, Issue 10, 1997, Pages 679-692

  Ishigooka, Jun ^a   Nagata, Etsuko ^a   Takahashi, Akihiko ^a   Sugiyama, Takeshi ^a   Uchiumi, Mitsutomo ^a   Tsukahara, Toshimasa ^a   Murasaki, Mitsukuni ^a   Miura, Sadanori ^b   Oguma, Takayoshi ^c   Yano, Yoshitaka ^c  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c SHIONOGI AND CO LTD   (Japan)

Author keywords

5 Hydroxytryptamine (serotonin); Duloxetine; Ex vivo; Platelet; Uptake inhibition

Indexed keywords

ANTIDEPRESSANT AGENT; DULOXETINE;

ADULT; ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; MALE; NORADRENALIN BRAIN LEVEL; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL;

EID: 0008923308     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(97)80102-6     Document Type: Article

References (19)

1. Preskorn SH, Burke MJ, Fast GA. Therapeutic drug monitoring. Principles and practice. Psychiatr Clin North Am. 1993;16:611-645.
2. Furlanut M, Benetello P, Spina E. Pharmacokinetic optimisation of tricyclic antidepressant therapy. Clin Pharmacokinet. 1993;24:301-318.
3. Lewonard BE. Pharmacological effects of serotonin reuptake inhibitors. J Clin Psychiatry. 1988;49:12-17.
4. 3H] Citalopram binding to brain and platelet membranes of human and rat. J Neurochem. 1991;56:248-252.
5. Ortiz J, Artigas F. Effects of monoamine uptake inhibitors on extracellular and platelet 5-hydroxytryptamine in rat blood: Different effects of clomipramine and fluoxetine. J Pharmacol. 1992;105:941-946.
6. Wong DT, Bymaster FP, Mayle DA, et al. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology. 1993;8:23-33.
7. Horng JS, Wong DT. Effects of serotonin uptake inhibitor, Lilly 110140, on transport of serotonin in rat and human blood platelets. Biochem Pharmacol. 1976;32:1287-1293.
8. Metzler CM, Elfring GL, McEwen AJ. A package of computer programs for pharmacokinetics modeling. Biometrics. 1974;30:562-563.
9. Lineweaver A, Burk D. The determination of enzyme dissociation constants. J Am Chem Soc. 1934;56:658-666.
10. Stahl SM, Meltzer HY. A kinetic and pharmacologic analysis of 5-hydroxytryptamine transport by human platelets and platelet storage granules: Comparison with central serotonergic neurons. J Pharmacol Exp Ther. 1978;205:118-132.
11. Marcusson JO, Ross SB. Binding of some antidepressants to the 5-hydroxytryptamine transporter in brain and platelets. Psychopharmacology. 1990;102:145-155.
12. Ishigooka J, Murasaki M, LY248686 Study Group. First open study with new antidepressant LY248686 (duloxetine) for depression in Japan. Eur Neuropsychopharmacol. 1996;6(Suppl 3):50. Abstract.
13. 14C-LY248686 maleate to rats. Eli Lilly's drugs metabolism and disposition report, 1991.
14. Ross SB, Aperia B, Beck-Friis J, et al. Inhibition of 5-hydroxytryptamine uptake in human platelets by antidepressant agents in vivo. Psychopharmacology. 1980;67:1-7.
15. 3H-imipramine binding. Acta Psychiatr Scand. 1990;82:330-334.
16. 3H]5HT uptake in human blood platelets: Changes after one week chlorimipramine treatment. Eur J Pharmacol. 1984;106:629-633.
17. 3H-paroxetine binding during treatment with psychoactive drugs. Biol Psychiatry. 1991;30:1056-1058.
18. Ross SB, Hall H, Renyi AL, Westerlund D. Effects of zimelidine on serotonergic and noradrenergic neurons after repeated administration in the rat. Psychopharmacology. 1981;72:219-225.
19. Hyttel J, Overo KF, Arnt J. Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram. Psychopharmacology. 1984;83:20-27.